Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Neoplasms Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Phase I/II Trial

NCT05153343 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT05153343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05153343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Neoplasms Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Phase I/II Trial
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
December 27, 2021
Completion date
March 19, 2025
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis，mf, myeloproliferative neoplasm (mpn)